Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy

Gemcitabine remains the standard of care for pancreatic cancer

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

A randomized phase III trial for advanced pancreatic cancer comparing gemcitabine with gemcitabine plus capecitabine has again demonstrated that combination chemotherapy provides no significant outcome advantage for patients. A marked change in treatment paradigm is essential if therapeutic interventions are to move beyond the persistently dismal outcome results for the majority of pancreatic cancer patients, as exemplified by the past decade of clinical research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jemal, A. et al. Cancer Statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).

    Article  PubMed  Google Scholar 

  2. Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960–1966 (2007).

    Article  CAS  PubMed  Google Scholar 

  3. Cunningham, D. et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2 7, 5513–5518 (2009).

    Article  Google Scholar 

  4. Scheithauer, W. et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann. Oncol. 14, 97–104 (2003).

    Article  CAS  PubMed  Google Scholar 

  5. Herrmann, R. et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreas cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Group. J. Clin. Oncol. 25, 2212–2217 (2007).

    Article  CAS  PubMed  Google Scholar 

  6. Tabernero, J. & Macarulla, T. Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. J. Clin. Oncol. 27, 5487–5491 (2009).

    Article  PubMed  Google Scholar 

  7. Philip, P. A. et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J. Clin. Oncol. 27, 5660–5669 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Vanderbilt Ingram Cancer Center, 691 Preston Building, Nashville, 37232, TN, USA

    Jordan Berlin

  2. Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Feinberg School of Medicine, Northwestern University, 676 N. St. Clair Street, Suite 850, Chicago, 60611, IL, USA

    Al B. Benson III

Authors
  1. Jordan Berlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Al B. Benson III
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Al B. Benson III.

Ethics declarations

Competing interests

The authors are Consultants and receive grant/research support from Roche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berlin, J., Benson III, A. Gemcitabine remains the standard of care for pancreatic cancer. Nat Rev Clin Oncol 7, 135–137 (2010). https://doi.org/10.1038/nrclinonc.2010.16

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.16

  • Springer Nature Limited

This article is cited by

Search

Navigation